Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000166370 | SCV000217160 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-05-02 | criteria provided, single submitter | clinical testing | The p.V1500M variant (also known as c.4498G>A), located in coding exon 34 of the TSC2 gene, results from a G to A substitution at nucleotide position 4498. The valine at codon 1500 is replaced by methionine, an amino acid with highly similar properties. In one functional study, this alteration was classified as probably neutral as it did not appear to impact inhibition of TORC1 (Hoogeveen-Westerveld M et al. Hum. Mutat., 2013 Jan;34:167-75). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Athena Diagnostics | RCV000518605 | SCV000615911 | uncertain significance | not specified | 2017-02-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000813618 | SCV000953985 | likely benign | Tuberous sclerosis 2 | 2024-09-19 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000813618 | SCV002040832 | uncertain significance | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000166370 | SCV002533546 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-11-26 | criteria provided, single submitter | curation | |
All of Us Research Program, |
RCV003996481 | SCV004817499 | uncertain significance | Tuberous sclerosis syndrome | 2023-07-19 | criteria provided, single submitter | clinical testing | This missense variant replaces valine with methionine at codon 1500 of the TSC2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies demonstrated no effect on TSC1 or TSC2 protein abundance, or on TSC1-TSC2 dependent inhibition of TORC1 activity (PMID: 22903760). This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 1/250308 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Tuberous sclerosis database |
RCV000055449 | SCV000083670 | not provided | Lymphangiomyomatosis; Tuberous sclerosis syndrome | no assertion provided | curation |